ARGX.BR · argenx SE

EURO STOXX 50 · Euronext Brussels

Risiko 7/10 · Biotech Pipeline · €772.00 ▼ 2.25%

Kennzahlen

• Price €772.00
• Market cap €48.3B
• P/E (ttm) 33.48
• Div yield none
• 52-wk range €511.60 – €833.60

Wichtigste Risiken

• Pipeline binary readout risk (Late-stage trial failures across FcRn indications) — HIGH
• Vyvgart reimbursement / pricing pressure (US payer pushback and IRA drug pricing reform) — HIGH
• Single-platform concentration (FcRn mechanism dependence across portfolio) — HIGH
• Commercial execution in new indications (Sales ramp in CIDP, PF, MG expansions) — MED

Fazit

Impressive multi-indication FcRn launch, but biotech binary risk and a premium growth multiple mean any clinical setback would trigger a sharp de-rating.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.